Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

BACKGROUND: Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the selection of eribulin or capecitabine in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamizawa, Shigemasa, Shimoi, Tatsunori, Satomi-Tsushita, Natsuko, Yazaki, Shu, Okuya, Toshihiro, Kojima, Yuki, Sumiyoshi-Okuma, Hitomi, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Noguchi, Emi, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759263/
https://www.ncbi.nlm.nih.gov/pubmed/35027011
http://dx.doi.org/10.1186/s12885-021-09112-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759263/
https://www.ncbi.nlm.nih.gov/pubmed/35027011
http://dx.doi.org/10.1186/s12885-021-09112-9

Ejemplares similares